Biogen abandons Aduhelm, its controversial drug against Alzheimer's. Drugmaker announced Wednesday that it would abandon ownership rights to aducanumab.
The drug had drawn fierce criticism after it was approved based on weak evidence. An FDA advisor called the drug's approval perhaps “the worst approval decision the FDA has made that I can remember. ” A congressional investigation later found that the FDA's process for approving Adu Helm was “riddled with irregularities” and involved “protocol flaws”